Dr John C. McKew promoted to Chief Operating Officer at Lumos Pharma
Lumos Pharma, Inc. has promoted Dr John McKew to the position of Chief Operating Officer effective 1 April 2020.
McKew is already Chief Scientific Officer and he will do both roles simultaneously. With his new role, he will lead Lumos’s clinical development plan as the company looks toward adding additional assets to its pipeline.
Rick Hawkins, the Chairman, CEO and President of the company commented on the promotion and said: “Dr. McKew has extensive experience in preclinical and clinical development of novel therapeutics across the private and public sector with myriad successes and demonstrated leadership in both realms.
“His prior work in the discovery and advancement of rare therapeutics offers critical support to Lumos Pharma’s clinical strategy, and his proven leadership capabilities serve to further strengthen our management team and the company at large.”
Prior to Lumos, McKew was Vice President of research at aTyr Pharma where he led a team advancing protein based therapeutics for rare disesaes. He has also served as the Acting Scientific Director for the National Center for Advancing Translational Science and has been part of the National Institute of Health. Priror to this he was a Director at Wyeth Research.
On his promotion, McKew said: “I am honored to assume the role of Chief Operating Officer and Chief Scientific Officer of Lumos Pharma and am excited to work with Rick and our team to advance the company toward our clinical and strategic goals.”
McKew is also an Adjunct Professor at Boston University’s School of Medicine. He graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry, completed his Ph.D. in Organic Chemistry at University of California